BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes 2024; 15(4): 724-734 [PMID: 38680706 DOI: 10.4239/wjd.v15.i4.724]
URL: https://www.wjgnet.com/1948-9358/full/v15/i4/724.htm
Number Citing Articles
1
Saeed Mohammadi, Ahmed Al-Harrasi. Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy?World Journal of Diabetes 2024; 15(9): 1847-1852 doi: 10.4239/wjd.v15.i9.1847
2
Jing Guo, Yi Cao, Qing-Yuan Wu, Lu-Sha Cen. Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathyWorld Journal of Diabetes 2024; 15(10): 2002-2005 doi: 10.4239/wjd.v15.i10.2002
3
Cornelius James Fernandez, Sahana Shetty, Joseph M Pappachan. Diabetic cardiomyopathy: Emerging therapeutic optionsWorld Journal of Diabetes 2024; 15(8): 1677-1682 doi: 10.4239/wjd.v15.i8.1677
4
Ashraf Al Madhoun. Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathyWorld Journal of Diabetes 2024; 15(8): 1654-1658 doi: 10.4239/wjd.v15.i8.1654
5
Lu Cai, Yi Tan, Md Shahidul Islam, Michael Horowitz, Kupper A Wintergerst. Diabetic cardiomyopathy: Importance of direct evidence to support the roles of NOD-like receptor protein 3 inflammasome and pyroptosisWorld Journal of Diabetes 2024; 15(8): 1659-1662 doi: 10.4239/wjd.v15.i8.1659